A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST).

Authors:

Abstract
2547 Background: Citarinostat is an oral, selective histone deacetylase 6 inhibitor that inhibits growth of solid tumor cell lines and exhibits potent synergy with Pac in preclinical studies. We conducted a phase 1b dose-escalation study evaluating the safety and preliminary antitumor activity of citarinostat plus Pac in pts with AST. Methods: Pts with AST, including those who progressed on prior taxane therapy, were enrolled in a 3+3 escalation study. Cohorts: 1) 180 mg, 2) 360 mg, or 3) 480 mg oral citarinostat d1-21, all plus 80 mg/m2 Pac d1, 8, 15 in a 28-day cycle. If no maximum tolerated dose (MTD) was identified, an additional cohort was allowed. Primary endpoints: dose limiting toxicity (DLT), MTD, and citarinostat recommended phase 2 dose (RP2D). Key secondary endpoints: safety, efficacy, and pharmacokinetics (PK). Results: Of 20 pts enrolled (cohort 1 = 3 pts, cohort 2 = 5 pts, cohort 3 = 6 pts, additional 360 mg cohort = 6 pts), 15 had prior taxane therapy. No DLTs were observed; MTD was not identified. Citarinostat RP2D was established at 360 mg/day. At 480 mg, a higher incidence and severity of neutropenia were observed (1 grade 4; 1 grade 3; 1 grade 2) vs 360 mg (1 grade 1). Common (≥ 25%) treatment-emergent adverse events (TEAEs): anemia (50%), alopecia (40%), hypomagnesemia (40%), decreased appetite (35%), fatigue (35%), diarrhea (30%), nausea (30%), leucopenia (25%), dehydration (25%), and vomiting (25%). Peripheral neuropathy was observed in 30% of pts (15% grade 3; 8 Pac-related events, 1 Pac/citarinostat-related). Twelve serious TEAEs were reported in 8 patients. No deaths were observed under treatment. Citarinostat did not modify the overall safety profile of Pac. Two pts had confirmed partial response (PR); of 14 pts with stable disease, 2 had unconfirmed PR. In preliminary PK analysis, citarinostat exposure increased in a dose-proportional manner from 180 mg to 360 mg; however, a decrease in exposure was observed after dosing at 480 mg Conclusions: Citarinostat plus Pac showed acceptable safety in heavily pretreated pts without any unexpected toxicities. Further investigations of efficacy are needed. Clinical trial information: NCT02551185.